| Species |
Human |
| Protein Construction |
CD21 (Ile21-Arg971)
Accession # P20023-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CD21, His, Human at 1μg/ml (100μl/well) on the plate can bind Anti-CD21 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
105.3 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 110-130 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD21 mRNA expression, an EBV-entry receptor, was transiently detected in NK cells after exosome treatment, and levels decreased after further culture. CD21 protein expression was also transiently transferred to NK cells after co-culture with an EBV-positive Burkitt lymphoma cell line (Raji) via trogocytosis. However, EBV did not infect NK cells through CD21-mediated trogocytosis. |
| Synonyms |
EBV receptor; CD21; C3DR; CR2; C3DRSLEB9; CVID7; SLEB9 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
